(Q53293104)

13 May 2018

title

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. (English)

1 reference

13 May 2018

multicenter clinical trial

main subject

1 reference

1

1 reference

13 May 2018

John Radford

14

1 reference

13 May 2018

Liselotte Højgaard

9

Liselotte Højgaard

1 reference

13 May 2018

13

Peter Johnson

1 reference

13 May 2018

Helén Almquist

7

Helén Almquist

1 reference

13 May 2018

Eva M Brun

6

Eva Brun

1 reference

13 May 2018

Wendi Qian

2

Wendi Qian

1 reference

13 May 2018

author name string

Edward J Somer

3

1 reference

13 May 2018

Antonella Franceschetto

4

1 reference

13 May 2018

Bruno Bagni

5

1 reference

13 May 2018

Annika Loft

8

1 reference

13 May 2018

Massimo Federico

10

1 reference

13 May 2018

Andrea Gallamini

11

1 reference

13 May 2018

Paul Smith

12

1 reference

13 May 2018

Michael J O'Doherty

15

1 reference

13 May 2018

publication date

27 May 2010

1 reference

13 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

13 May 2018

volume

37

1 reference

13 May 2018

issue

10

1 reference

13 May 2018

page(s)

1824-1833

1 reference

13 May 2018

PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients

cites work

1 reference

12 December 2020

Evaluation of response: is 18F-FDG PET the answer?

1 reference

12 December 2020

Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology

1 reference

12 December 2020

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

1 reference

12 December 2020

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

12 December 2020

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

1 reference

12 December 2020

Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging

1 reference

12 December 2020

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

1 reference

12 December 2020

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

1 reference

12 December 2020

Interobserver variability in the detection of cervical-thoracic Hodgkin's disease by computed tomography.

1 reference

12 December 2020

Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma

1 reference

12 December 2020

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

1 reference

12 December 2020

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

1 reference

12 December 2020

PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

1 reference

12 December 2020

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma

1 reference

12 December 2020

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

12 December 2020

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

12 December 2020

FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study.

1 reference

12 December 2020

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

1 reference

12 December 2020

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

12 December 2020

PET/CT for therapy response assessment in lymphoma

1 reference

12 December 2020

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

1 reference

12 December 2020

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

1 reference

12 December 2020

Limitations of PET for imaging lymphoma

1 reference

12 December 2020

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

1 reference

12 December 2020

10.1007/S00259-010-1490-5

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018